Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
Syntholene Selects Papadakis Engineering as Integration Partner for Novel Thermal-Hybrid Synthetic Fuel Demonstration Facility Heat Exchanger System
Silver Hammer Prepares for Drill Program at Its 100% Owned California Patented Claim at The Eliza Project in Nevada
